ALDX
Aldeyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.48
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 66.6K | — | — | — | — |
| Gross Profit | (66.6K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 15.6M | 25.7M | 48.2M | 29.5M | 47.3M |
| SG&A Expense | 1137.4B | 9.6M | 11.9M | 13.3M | 15.4M |
| General & Admin Expense | 1137.4B | 9.6M | 11.9M | 13.3M | 15.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1137.3B) | — | — | — | — |
| Total Operating Expenses | 24.0M | 35.3M | 60.1M | 42.8M | 62.7M |
| Cost and Expenses | 24.1M | 35.3M | 60.1M | 42.8M | 62.7M |
| Operating Income (EBIT) | (24.1M) | (35.3M) | (60.1M) | (42.8M) | (62.7M) |
| Non-Operating | |||||
| Interest Income | 2.4M | 3.3M | 6.2M | 7.3M | 2.3M |
| Interest Expense | 1.4M | 1.9M | 1.9M | 2.1M | 1.7M |
| Net Interest Income | 1.0M | 1.4M | 4.3M | 5.3M | 655.4K |
| Other Non-Op Income/Expense | 1.0M | 1.4M | 4.3M | 5.3M | 655.4K |
| Non-Operating Income (excl Interest) | (2.4M) | (3.3M) | (6.2M) | (7.3M) | (2.3M) |
| EBT (Pre-Tax Income) | (23.1M) | (33.8M) | (55.9M) | (37.5M) | (62.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (23.1M) | (33.8M) | (55.9M) | (37.5M) | (62.0M) |
| Earnings from Cont. Ops | (23.1M) | (33.8M) | (55.9M) | (37.5M) | (62.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (23.1M) | (33.8M) | (55.9M) | (37.5M) | (62.0M) |
| Per Share | |||||
| Basic EPS | ($0.39) | ($0.56) | ($0.94) | ($0.64) | ($1.06) |
| Diluted EPS | ($0.39) | ($0.56) | ($0.94) | ($0.64) | ($1.06) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 60.3M | 60.1M | 59.5M | 58.9M | 58.4M |
| Diluted Shares Outstanding | 60.3M | 60.1M | 59.5M | 58.9M | 58.4M |
| Profitability Metrics | |||||
| EBITDA | (21.4M) | (31.7M) | (53.7M) | (35.2M) | (60.1M) |
| D&A | 266.1K | 252.0K | 249.6K | 262.8K | 258.7K |
| EBIT | (21.6M) | (31.9M) | (53.9M) | (35.5M) | (60.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026